This systematic review focused on 18 studies evaluating the implementation of GLP-1 RAs in obesity-related HFpEF, including semaglutide (2.4 mg weekly) and tirzepatide (up to 15 mg weekly). The gene discussed is GLP1R; the disease is Obesity.